These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19175871)

  • 1. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
    Poynard T; Ngo Y; Marcellin P; Hadziyannis S; Ratziu V; Benhamou Y;
    J Viral Hepat; 2009 Mar; 16(3):203-13. PubMed ID: 19175871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Sievert W; Tong M; Arterburn S; Borroto-Esoda K; Frederick D; Rousseau F
    Hepatology; 2008 Sep; 48(3):750-8. PubMed ID: 18752330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment.
    Fan X; Fang D; Bin D; Xueyong L; Jun C; Hongshan W
    Antivir Ther; 2009; 14(8):1149-56. PubMed ID: 20032544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B].
    Li J; Zhao H; Si CW; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):270-2. PubMed ID: 17971943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
    Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
    Uyar C; Akcam FZ; Ciris M; Kaya O; Kockar C; Isler M
    Indian J Pathol Microbiol; 2010; 53(3):470-5. PubMed ID: 20699505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
    Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF
    Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
    Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
    Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
    Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.